Multiple Myeloma

Company reports advances in lymphoma, multiple myeloma therapy at ASCO

Published in Cancer Weekly, July 6th, 2004

Immunomedics, Inc., (IMMU) announced two potential products showed promising activity in the treatment of aggressive non-Hodgkin lymphoma (NHL), and a new product candidate is showing high activity in a human multiple myeloma animal model.

A pilot clinical study of epratuzumab, Immunomedics' humanized anti-CD22 monoclonal antibody, in combination with rituximab and CHOP (cyclophosphamide, doxorubicin hydrochloride, Oncovin (vincristine), and prednisone) chemotherapy (ER-CHOP), was studied in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) to assess safety and activity (Poster 6580).

Conducted by the Eastern Oncology...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry